

Resource Summary Report

Generated by RRID on Aug 4, 2026

BioReliance

RRID:SCR_003791

Type: Tool

Proper Citation

BioReliance (RRID:SCR_003791)

Resource Information

URL: <http://www.bioreliance.com/>

Proper Citation: BioReliance (RRID:SCR_003791)

Description: Company that provides testing and manufacturing services to pharmaceutical and biopharmaceutical companies that span the product cycle from early pre-clinical development to licensed production.

Abbreviations: BREL

Synonyms: BioReliance Corporation, BioReliance Corp.

Resource Type: commercial organization

Keywords: testing, manufacturing, pharmaceutical, biopharmaceutical

Resource Name: BioReliance

Resource ID: SCR_003791

Alternate IDs: nlx_158085

Record Creation Time: 20220129T080221+0000

Record Last Update: 20260801T190225+0000

Ratings and Alerts

No rating or validation information has been found for BioReliance.

No alerts have been found for BioReliance.

Data and Source Information

Usage and Citation Metrics

We found 62 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Won S, et al. (2023) Mass-produced gram-negative bacterial outer membrane vesicles activate cancer antigen-specific stem-like CD8⁺ T cells which enables an effective combination immunotherapy with anti-PD-1. *Journal of extracellular vesicles*, 12(8), e12357.

Kuo B, et al. (2022) Comprehensive interpretation of in vitro micronucleus test results for 292 chemicals: from hazard identification to risk assessment application. *Archives of toxicology*, 96(7), 2067.

Kindermann J, et al. (2022) Orthopox viruses and the safety margins of solvent-detergent treated plasma-derived medicinal products. *Transfusion*, 62(12), 2454.

Monath TP, et al. (2022) Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential. *PLoS pathogens*, 18(6), e1010658.

Ambroso JL, et al. (2022) Assessment of the Carcinogenic Potential of Pretomanid in Transgenic Tg.rasH2 Mice. *International journal of toxicology*, 41(5), 367.

Gill MW, et al. (2022) Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278. *Toxicology and applied pharmacology*, 438, 115885.

Mukhopadhyay E, et al. (2022) Production of a high purity, C-tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in *Pichia pastoris* under cGMP conditions. *Biotechnology and bioengineering*, 119(10), 2784.

Elfassy A, et al. (2021) Development and clinical validation of an automated cell cytotoxicity neutralization assay for detecting *Clostridioides difficile* toxins in clinically relevant stools samples. *Anaerobe*, 71, 102415.

Gamino V, et al. (2021) Pathogenesis of Two Western Mediterranean West Nile Virus Lineage 1 Isolates in Experimentally Infected Red-Legged Partridges (*Alectoris rufa*). *Pathogens (Basel, Switzerland)*, 10(6).

Uckun FM, et al. (2021) A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. *Cancers*, 13(16).

Ji Z, et al. (2021) Assessment of cellular and molecular metrics for dose selection in an in vivo comet assay: A case study with MDI. *Environmental and molecular mutagenesis*, 62(8), 446.

Escribano-Romero E, et al. (2021) Previous Usutu Virus Exposure Partially Protects Magpies (*Pica pica*) against West Nile Virus Disease But Does Not Prevent Horizontal Transmission. *Viruses*, 13(7).

Carneiro PP, et al. (2021) Blockade of TLR2 and TLR4 Attenuates Inflammatory Response and Parasite Load in Cutaneous Leishmaniasis. *Frontiers in immunology*, 12, 706510.

Laurent A, et al. (2021) Optimized Manufacture of Lyophilized Dermal Fibroblasts for Next-Generation Off-the-Shelf Progenitor Biological Bandages in Topical Post-Burn Regenerative Medicine. *Biomedicines*, 9(8).

Besaratinia A, et al. (2021) Hydroxychloroquine induces oxidative DNA damage and mutation in mammalian cells. *DNA repair*, 106, 103180.

Valentine CC, et al. (2020) Direct quantification of in vivo mutagenesis and carcinogenesis using duplex sequencing. *Proceedings of the National Academy of Sciences of the United States of America*, 117(52), 33414.

Ladics GS, et al. (2020) Safety evaluation of a novel variant of consensus bacterial phytase. *Toxicology reports*, 7, 844.

Yamano-Adachi N, et al. (2020) Establishment of fast-growing serum-free immortalised cells from Chinese hamster lung tissues for biopharmaceutical production. *Scientific reports*, 10(1), 17612.

Laurent A, et al. (2020) Bringing Safe and Standardized Cell Therapies to Industrialized Processing for Burns and Wounds. *Frontiers in bioengineering and biotechnology*, 8, 581.

Chen YH, et al. (2020) Rapid Lentiviral Vector Producer Cell Line Generation Using a Single DNA Construct. *Molecular therapy. Methods & clinical development*, 19, 47.